Does Dr. MARIO CASTRO have financial conflicts of interest?

Dr. MARIO CASTRO (MD) has received a total of $1,232,536 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,186,575 in personal promotional payouts (consulting, meals, travel) and $45,962 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARIO CASTRO?

According to CMS Open Payments data, Dr. MARIO CASTRO received funding from GENZYME CORPORATION ($698,055), ASTRAZENECA PHARMACEUTICALS ($220,738), and REGENERON HEALTHCARE SOLUTIONS ($126,099).

Does Dr. MARIO CASTRO receive research grants or speaking fees?

Dr. MARIO CASTRO has received $1,186,575 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $45,962 in clinical research grants.

DR. MARIO CASTRO

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: KANSAS CITY, KS 66160

NPI Number: 1881610004

LIFETIME INDUSTRY VALUE

$1,232,536

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. CASTRO is a verified Internal Medicine, Pulmonary Disease practitioner based in KANSAS CITY, KS.

Between 2021 and 2025, Dr. CASTRO had an overall industry promotional and research financial footprint of $1,232,536 as recorded in the federal CMS Open Payments database.

$1,186,575 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$45,962 was allocated to sponsored clinical trials and medical research activities.

Dr. CASTRO's primary funding source is GENZYME CORPORATION, which accounts for $698,055 (representing 56.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENZYME CORPORATION

Rank 1

$698,055

56.6%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$220,738

17.9%

REGENERON HEALTHCARE SOLUTIONS

Rank 3

$126,099

10.2%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.